Systematic Examination of Health Inequalities: Documentation, Patterns, and Determinants (CHANCE)
Assessment of Lifestyle Parameters and Biomarkers of Biochemistry and Physiology to Address Health Inequalities: An Exploratory Cohort Study
Przegląd badań
Status
Status
Warunki
Warunki
Szczegółowy opis
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Kontakty i lokalizacje
Kontakt w sprawie studiów
Kontakt w sprawie studiów
- Nazwa: Aristidis S Veskoukis, Associate Professor
- Numer telefonu: 0030 2431047114
- E-mail: veskoukis@uth.gr
Lokalizacje studiów
-
-
-
Larissa, Grecja
- Jeszcze nie rekrutacja
- General Hospital of Larissa
-
Kontakt:
- Grigoris Vlachakis
- Numer telefonu: 0030 2413504100
- E-mail: gen.nosokomeio.laris@ghl.gr
-
Larissa, Grecja
- Rekrutacyjny
- Health structures in the Region of Thessaly
-
Kontakt:
- Maria Papagianni
- Numer telefonu: 0030 2431047115
- E-mail: mpapag@uth.gr
-
Larissa, Grecja
- Jeszcze nie rekrutacja
- National Organization for the Prevention and Treatment of Addictions (EOPAE)
-
Kontakt:
- Vasilis Pinakas
- Numer telefonu: 0030 2410671842
- E-mail: vpinakas@gmail.com
-
Trikala, Grecja
- Jeszcze nie rekrutacja
- General Hospital of Trikala
-
Kontakt:
- Lia Roganaki, Hospital Administrator
- E-mail: gnt.dioikitis@trikalahospital.gr
-
Trikala, Grecja
- Jeszcze nie rekrutacja
- National Organization for the Prevention and Treatment of Addictions (EOPAE), Trikala
-
Kontakt:
- Marina Papageorgiou
- Numer telefonu: 0030 2431026481
- E-mail: papageorgiou.marina5@gmail.com
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
- Dorosły
- Starszy dorosły
Akceptuje zdrowych ochotników
Metoda próbkowania
Badana populacja
Opis
Inclusion Criteria:
- Adults (>18 years of age)
- All healthy individuals who reside in rural and urban areas
- All patients with non-communicable diseases who reside in rural and urban areas
- Patients with opioid use disorders under medication for addiction treatment with methadone and buprenorphine
- Individuals incarcerated in correctional facilities
Exclusion Criteria:
- Minors (<18 years of age)
- Individuals with communicable diseases
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
Liczba grup / kohort
Kohorty i interwencje
Grupa / KohortaGrupa / Kohorta |
|---|
|
Patients with non-communicable diseases - residents of rural areas
No intervention
|
|
Patients with non-communicable diseases - residents of urban areas
No intervention
|
|
Healthy volunteers - residents of rural areas
No intervention
|
|
Healthy volunteers - residents of urban areas
No intervention
|
|
Patients with opioid use disorders under medication for addiction treatment
No intervention
|
|
Individuals incarcerated in correctional facilities (prisons)
No intervention
|
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Demographic data
Ramy czasowe: Data will be collected at Baseline
|
Body mass index, smoking, alcohol consumption, place of residence, health insurance, educational status, family status and financial status will be collected among others through a questionnaire.
|
Data will be collected at Baseline
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Physical activity
Ramy czasowe: Data will be collected at Baseline
|
It will be measured through the international physical activity questionnaire (IPAC)
|
Data will be collected at Baseline
|
|
Quality of life
Ramy czasowe: Data will be collected at Baseline
|
It will be measured through the SF-36 questionnaire.
This instrument has a physical component and a mental component.
Each domain is scored from 0 to 100.
Higher score = better health or better quality of life.
|
Data will be collected at Baseline
|
|
Heroin craving
Ramy czasowe: Data will be collected at Baseline
|
It will be measured using the heroin craving questionnaire (HCQ).
The score is calculated with a 7-point Likert scale ranging from 1 (i.e., strongly disagree) to 7 (i.e., strongly agree).
Higher values = higher craving for heroin use.
It applies only to the patients with opioid use disorders.
|
Data will be collected at Baseline
|
|
Concentration of reduced glutathione (GSH)
Ramy czasowe: Data will be collected at Baseline
|
The concentration of GSH, a crucial antioxidant metabolite, will be measured in the blood of sub-population of the volunteers
|
Data will be collected at Baseline
|
|
Concentration of protein carbonyls
Ramy czasowe: Data will be collected at Baseline
|
Concentration of protein carbonyls, a biomarker of protein oxidation, will be measured in the blood of sub-population of the volunteers
|
Data will be collected at Baseline
|
|
Total antioxidant capacity (TAC)
Ramy czasowe: Data will be collected at Baseline
|
TAC is crude biomarker of antioxidant status and will be measured in the blood of sub-population of the volunteers
|
Data will be collected at Baseline
|
|
Activity of catalase
Ramy czasowe: Data will be collected at Baseline
|
Activity of catalase, a substantial antioxidant enzyme, will be measured in blood of sub-population of the volunteers
|
Data will be collected at Baseline
|
|
Cardiorespiratory fitness
Ramy czasowe: Data will be collected at Baseline
|
A marker, which is associated to physical activity and health status, will be measured in sub-population of the volunteers.
In particular, resting energy expenditure and resting heart rate will be assessed through metabolic gas analyzer.
|
Data will be collected at Baseline
|
|
Body fat percentage
Ramy czasowe: Data will be collected at Baseline
|
It is associated to physical activity and health status and will be measured in sub-population of the volunteers through bioelectrical impedance analysis.
|
Data will be collected at Baseline
|
|
Lean body mass
Ramy czasowe: Data will be collected at Baseline
|
It is associated to physical activity and health status and will be measured (in kg) in sub-population of the volunteers through bioelectrical impedance analysis.
|
Data will be collected at Baseline
|
|
Muscle mass
Ramy czasowe: Data will be collected at Baseline
|
It is associated to physical activity and health status and will be measured (in kg) in sub-population of the volunteers through bioelectrical impedance analysis.
|
Data will be collected at Baseline
|
Współpracownicy i badacze
Sponsor
Sponsor
Współpracownicy
Współpracownicy
Publikacje i pomocne linki
Publikacje ogólne
- Veskoukis AS, Tsatsakis A, Kouretas D. Approaching reactive species in the frame of their clinical significance: a toxicological appraisal. Food and Chemical Toxicology, 138:111206, 2020.
- Veskoukis AS, Kerasioti E, Priftis A, Kouka P, Spanidis Y, Makri S, Kouretas D. A battery of translational biomarkers for the assessment of the in vitro and in vivo antioxidant action of plant polyphenolic compounds: the biomarker issue. Current Opinion in Toxicology, 13:99-109, 2019.
- Veskoukis AS, Margaritelis NV, Kyparos A, Paschalis V, Nikolaidis MG. Spectrophotometric assays for measuring redox biomarkers in blood and tissues: the NADPH network. Redox Report, 23(1):47-56, 2018.
- Veskoukis AS, Kyparos A, Paschalis V, Nikolaidis MG. Spectrophotometric assays for measuring redox biomarkers in blood. Biomarkers, 21(3):208-17, 2016.
- Dinas PC, On Behalf Of The Students Of Module Introduction To Systematic Reviews, Karaventza M, Liakou C, Georgakouli K, Bogdanos D, Metsios GS. Combined Effects of Physical Activity and Diet on Cancer Patients: A Systematic Review and Meta-Analysis. Nutrients. 2024 Jun 2;16(11):1749. doi: 10.3390/nu16111749.
- Metsios GS, Moe RH, van der Esch M, van Zanten JJCSV, Fenton SAM, Koutedakis Y, Vitalis P, Kennedy N, Brodin N, Bostrom C, Swinnen TW, Tzika K, Niedermann K, Nikiphorou E, Fragoulis GE, Vlieland TPVM, Van den Ende CHM, Kitas GD; IMPACT-RMD Consortium. The effects of exercise on cardiovascular disease risk factors and cardiovascular physiology in rheumatoid arthritis. Rheumatol Int. 2020 Mar;40(3):347-357. doi: 10.1007/s00296-019-04483-6.
- Metsios GS, Moe RH, Kitas GD. Exercise and inflammation. Best Pract Res Clin Rheumatol. 2020 Apr;34(2):101504. doi: 10.1016/j.berh.2020.101504.
- Poulter M, Coe S, Graham CA, Leach B, Tammam J. A systematic review of the effect of dietary and nutritional interventions on the behaviours and mental health of prisoners. Br J Nutr. 2024 Jul 14;132(1):77-90. doi: 10.1017/S0007114524000849.
- da Costa, F.A.; Verschuuren, M.; Andersen, Y.; Stürup-Toft, S.; Lopez-Acuña, D.; Ferreira-Borges, C. The WHO Prison Health Framework: A framework for assessment of prison health system performance. Eur. J. Public Health 2022, 32, 565-570.
- Schoenthaler, S., Gast, D., Giltay, E. J., & Amos, S. (2023). The Effects of Vitamin-Mineral Supplements on Serious Rule Violations in Correctional Facilities for Young Adult Male Inmates: A Randomized Controlled Trial. Crime & Delinquency, 69(4), 822-840.
- Leventelis C, Barmpas PT, Nellas I, Tasoulis S, Veskoukis AS, Tsironi M. COVID-19 Pandemic Detrimentally Affects Craving and Quality of Life in Patients Under Medication-Assisted Treatment with Buprenorphine and Methadone: The Issue of Medication Dose. Psychiatry International, 5, 867-882, 2024.
- Leventelis C, Makri S, Ververi A, Papageorgiou K, Tentolouri A, Mountzouridi E, Tekos F, Barmpas PT, Tasoulis S, Metsios GS, Kouretas D, Veskoukis AS. Pomegranate juice ameliorates craving and oxidative stress on patients under medication for opioid addiction treatment with methadone and buprenorphine: a Ranzomised Controlled Trial. Clinical Nutrition ESPEN, 66, 34-44, 2025a.
- Leventelis C, Veskoukis AS, Rojas Gil AP, Papadopoulos P, Garderi M, Angeli A, Kampitsi A, Tsironi M. Methadone and Buprenorphine as Medication for Addiction Treatment Diversely Affect Inflammation and Craving Depending on Their Doses. Pharmacy (Basel), 13(2), 40, 2025b.
- Leventelis C, Barmpas PT, Kampitsi A, Iliopoulou K, Toutouktsi N, Malakopoulos P, Tasoulis S, Veskoukis AS. Pomegranate juice consumption improves sleep quality and melatonin concentration of patients with opioid use disorders under medication-assisted treatment with methadone and buprenorphine: a randomized controlled trial. Substance Use and Addiction Journal, 46(4):981-993, 2025c.
- Edwards, A., Hung, R., Levin, J. B., Forthun, L., Sajatovic, M., & McVoy, M. (2023). Health disparities among rural individuals with mental health conditions: A systematic literature review. Rural Mental Health, 47(3), 163-178. https://doi.org/10.1037/rmh0000228
- Cosgrave, C., Malatzky, C., & Gillespie, J. (2019). Social determinants of health and the rural health care gap: A scoping review. International Journal of Environmental Research and Public Health, 18(8), 2668. https://doi.org/10.3390/ijerph16030314
- Probst, J. C., Eberth, J. M., & Crouch, E. (2019). Structural urbanism contributes to poorer health outcomes for rural America. Health Affairs, 39(12), 2017-2024. https://doi.org/10.1377/hlthaff.2019.00914
- Holt-Lunstad, J. (2018). Why social relationships are important for physical health: A systems approach to understanding and modifying risk and protection. Annual Review of Psychology, 69, 437-458. https://doi.org/10.1146/annurev-psych-122216-011902
- Umberson, D., & Donnelly, R. (2023). Social isolation: An unequally distributed health hazard. Annual Review of Sociology, 49(1), 379-399. https://doi.org/10.1146/annurev-soc-031021-012001
- Aldridge, R. W., Story, A., Hwang, S. W., Nordentoft, M., Luchenski, S. A., Hartwell, G., & Hayward, A. C. (2018). Morbidity and mortality in homeless individuals, prisoners, sex workers, and individuals with substance use disorders in high-income countries: A systematic review and meta-analysis. https://doi.org/10.1016/S0140-6736(17)31869-X
- Tsai, J., O'Toole, T., & Kearney, L. K. (2017). Homelessness as a public mental health and social problem: New knowledge and solutions. Psychological Services, 14(2), 113-117. https://doi.org/10.1037/ser0000164
- Luchenski, S., Maguire, N., Aldridge, R. W., et al. (2018). What works in inclusion health: Effective interventions for marginalised and excluded populations. The Lancet, 391(10117), 266-280. https://doi.org/10.1016/S0140-6736(17)31959-1
- Triantafyllou, C., Latsou, D., Psiakis, V., Pierrakos, G., & Breda, J. (2025). Addressing health inequalities in Greece: A comprehensive framework for socioeconomic determinants of health. Healthcare, 13(19), 2394. https://doi.org/10.3390/healthcare13192394
- Krieger N. A glossary for social epidemiology: part II. J Epidemiol Community Health. 2001;55(55):693-700. doi: 10.1136/jech.55.10.693.
- OECD. (2025a). Health at a Glance 2025: OECD indicators. OECD Publishing. https://www.oecd.org/en/publications/health-at-a-glance-2025_8f9e3f98-en.html
- OECD. (2023). Health at a Glance: Europe 2023. https://www.oecd.org/en/publications/health-at-a-glance-2023_7a7afb35-en.html
- Douki, S., & Spyridakis, E. (2004). Inequalities in access to health services: The case of Greece. HAPSc Policy Briefs Series, 5(2), 27. https://doi.org/10.12681/hapscpbs.40777
- World Health Organization. (2025a). World report on social determinants of health equity 2025. WHO. https://www.who.int/teams/social-determinants-of-health/equity-and-health/world-report-on-social-determinants-of-health-equity
- World Health Organization. (2021). Social determinants of health and health inequalities in Europe. WHO Regional Office for Europe. https://www.who.int/europe/health-topics/social-determinants-of-health
- McCartney, G., Popham, F., McMaster, R., & Cumbers, A. (2019). Defining health and health inequalities. Public Health, 172, 22-30. https://doi.org/10.1016/j.puhe.2019.03.023
- Sartorius, N. (2006). The meanings of health and its promotion. Croatian Medical Journal, 47(4), 662-664. https://pmc.ncbi.nlm.nih.gov/articles/PMC2080455/
- World Health Organization. (2014). Basic documents (48th ed.). WHO.
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- 98 / 25.07.2025
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .